These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38845861)

  • 21. Disulfidptosis-related Protein RPN1 may be a Novel Anti-osteoporosis Target of Kaempferol.
    Pan C; Zhang C; Lin Z; Liang Z; Cui Y; Shang Z; Wei Y; Chen F
    Comb Chem High Throughput Screen; 2024; 27(11):1611-1628. PubMed ID: 38213143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
    Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
    Front Oncol; 2022; 12():998336. PubMed ID: 36185230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifies microtubule-binding protein
    Wang W; Zhang J; Wang Y; Xu Y; Zhang S
    Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 27. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
    Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
    Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The disulfidptosis-related signature predicts prognosis and immune features in glioma patients.
    Wang X; Yang J; Yang F; Mu K
    Sci Rep; 2023 Oct; 13(1):17988. PubMed ID: 37864127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
    Dong X; Liu T; Li Z; Zhai Y
    Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
    Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
    Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
    Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
    Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
    Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
    Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment.
    Wu Z; Pan T; Li W; Zhang YH; Guo SH; Liu Y; Zhang L; Wang ZY
    Clin Transl Oncol; 2024 Oct; 26(10):2701-2717. PubMed ID: 38642258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
    Xiong Y; Kong X; Mei H; Wang J; Zhou S
    Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.